Partnerships

In addition to the vaccines developed in-house, we offer selected product candidates and technologies to third parties for commercial collaborations and co-development partnerships.

Currently, Intercell is involved in the development of vaccines with some of the global leading key players within the vaccine and pharmaceutical industry:

Indication

Partner

Japanese Encephalitis Virus (JEV) vaccine

Novartis / CSL / Biological E. Ltd.

Hepatitis C Virus (HCV) vaccine 

Romark

Pandemic Influenza vaccine patch

GSK/HHS

Tuberculosis vaccine

Statens Serum Institut / sanofi-aventis/ AERAS

IC31® adjuvant in different (Flu + undisclosed bacterial target)

Novartis

In addition, we have cooperative research and development agreements in place with:

  • The Centers for Disease Control and Prevention (Streptococcus pneumoniae vaccine)
  • The PATH Malaria Vaccine Initiative (Malaria vaccine)
  • The National Institutes of Health, U.S. Department of Health & Human Services
  • Boehringer Ingelheim Vetmedica